



***Program - 5th Pituitary Congress***  
**Sunday June 28, 1998 - Tuesday June 30, 1998**

- Session 1: Plenary Session**  
*Moderators:* Giovanni Faglia and Steven Lamberts
- 4:15 - 5:00 PM Development of the pituitary  
Kathy Mahon
- 5:00 - 5:45 Neuroendocrinological actions and implications of leptin  
Felipe Casanueva
- 6:00 - 9:00 Poster session and Reception
- MONDAY**
- Session 2: New insight into pituitary disease provided by genetic disruption**  
*Moderators:* Hiroshi Demura and Larry Jameson
- 8:00 - 8:30 AM Pit 1 and prop 1 phenotypes - clinical aspects  
R. Pfaffle
- 8:30 - 9:00 Dopamine D2 Receptor knockout mice  
Malcolm Low
- 9:00 - 9:30 Transgenic models to elucidate the roles of inhibin and activin in reproduction, oncogenesis and development.  
Martin Matzuk
- 10:00 - 10:30 *Coffee Break*
- Session 3: Advances in Prolactinomas**  
*Moderators:* Gaetano Lombardi and Peter Snyder
- 10:30 - 11:00 AM New therapies of prolactinomas  
Jonathan Webster
- 11:00 - 11:30 Recurrent and resistant prolactinomas  
Mary Lee Vance
- 11:30 - 12:00 Pregnancy and prolactinomas  
Mark Molitch
- 12:00 - 2:00 **Luncheon Seminars**
- Session 4: Genetics of Pituitary Tumors**  
*Moderators:* Julian Davis and Ana Spada
- 2:00 - 2:30 Molecular mechanisms of pituitary oncogenesis: an overview

PM Shlomo Melmed

2:30 - 3:00 Menin: the story unfolds  
Allen Spiegel

3:00 - 3:30 Methylation mechanisms in pituitary tumorigenesis  
William Farrell, Ph.D.

3:30 - 4:00 *Coffee Break*

**Session 5: The growth hormone neuroendocrine axis - new developments**  
*Moderators:* Gloria S Tannenbaum and Michael Thorner

4:00 - 4:30 Hypothalamic networks involved in the control of GH secretion  
PM Iain CAF Robinson

4:30 - 5:00 Somatostatin receptor subtypes: functions and regulation  
Agnes Schonbrunn

5:00 - 5:30 Growth hormone releasing peptides  
Roy Smith

5:30 - 6:00 Pituitary Society Business Meeting & Awards  
Presentation by (get name from Mary Lee and David)

6:00 - 6:30 Presidential Address (get name from Mary Lee)

Evening free

## TUESDAY

**Session 6: Plenary Session**  
*Moderators:* Iain Clarke and Patricia Hinkle

7:45 - 8:30 Mechanistic and functional insights derived from pituitary cell  
AM strains in culture  
Armen H. Tashjian Jr.

**Session 7: Novel actions of pituitary hormones**  
*Moderators:* Charles Clevenger and Karin Eidne

8:30 - 9:00 Actions of the growth hormone/prolactin family of proteins in the  
AM placenta  
Daniel Linzer

9:00 - 9:30 Growth hormone and IGF effects on bone  
Anne Klibanski

9:30 - 10:00 Effect of pituitary hormones on mammary tissue  
David Kleinberg

10:00 - 10:30 *Coffee Break*

**Session 8: Hot Topics**  
*Moderators:* Robert Gagel and Agnes Schonbrunn

10:30 - 10:45 Different retinoid compounds suppress TSHbeta promoter activity  
AM in vitro and the thyrotrope-restricted isoform RXR $\gamma$ 1 appears to mediate this effect  
Bryan Haugen

- 10:45 - 11:00 Pituitary-Thyroid axis alterations during use of an RXR-selective retinoid analog  
Steven I. Sherman
- 11:00 - 11:15 Identification and functional characterization of an intermediate isoform of the human prolactin receptor  
Charles V. Clevenger
- 11:15 - 11:30 A pituitary adenoma in a family with a mutant calcium-sensing receptor. A role of this mutant receptor in pituitary oncogenesis?  
Ana O. Hoff
- 11:30 - 11:45 Targeted ablation of gonadotrophs in transgenic mice affects early development of lactotrophs  
Hugo Vankelecom, University of Leuven, Belgium
- 11:45 - 12:00 POMC and Somatostatin knockout mice: clinically relevant phenotypes  
Ute Hochgeschwender
- 12:00 - 12:15 Progesterone binds to the oxytocin receptor and inhibits receptor signalling: A novel non-genomic steroid action  
Hans H. Zingg
- 12:15 - 12:30 A Phase I study of a novel vasopressin receptor antagonist, VPA-985, a potential therapeutic agent for vasopressin-mediated hyponatremia  
Gayle P. Orczyk
- 12:30 - 2:30 **Luncheon Seminars**
- Session 9: Pituitary development and regulation**  
*Moderators:* Keith Friend and Stafford Lightman
- 2:30 - 3:00 PM Pituitary specific estrogen receptors  
Margaret A. Shupnik
- 3:00 - 3:30 Paracrine interactions in pituitary cell function  
Gwen Childs
- 3:30 - 4:00 Model Pituitary Cell lines from Transgenic Mice  
Nira Ben-Jonathan
- 4:00 - 4:30 *Coffee Break*
- Session 10: Growth Hormone - too little, too much**  
*Moderators:* Jens Christiansen and Ken Ho
- 4:30 - 5:00 PM The evolving field of growth hormone antagonists: Basic Studies  
John Kopchick
- 5:00 - 5:30 Pathophysiology of dominant negative growth hormone mutations  
Priscilla Dannies
- 5:30 - 6:00 Clinical studies with growth hormone antagonists  
David Clemmons
- 6:00 - 6:30 Metabolic basis of adult growth hormone replacement  
Jens Otto Jorgensen
- 6:30 **Closing remarks**

7:30

*Beach Banquet*

**Luncheon Seminars (80 min)**

*All sessions to run concurrently on Monday and Tuesday*

**1. Management of difficult pituitary cases**

*Moderator:* Ivor Jackson

**Panel:** Ian McCutcheon      David M. Cook  
Akira Shimatzu      Sylvia Asa  
Brooke Swearingen      Paolo Beck-Peccoz  
Lynette Kaye Nieman

Cases to be presented by panel members

**2. Clinical uses of CRH and management of Cushing's Syndrome**

*Moderator:* James Findling

**Speakers:** George Chrousos  
Beverly Biller  
Xavier Bertagna

**3. Uses of pituitary irradiation in management of pituitary tumors**

*Moderator:* Kalmon Post

Edward Laws      Gamma knife  
Jay Loeffler      Fractionated conformal radiotherapy  
Ariel Barkan      Conventional radiation in the treatment of acromegaly

**4. Somatostatin and growth hormone releasing peptides: clinical uses**

*Moderator:* Michael Sheppard

Steven      Somatostatin receptor mediated radio and  
Lamberts      chemotherapy  
Phillipe Jaquet      Lanreotide vs. Sandostatin LAR  
Ezio Ghigo      Growth hormone releasing peptides

**5. Genetic testing**

*Moderator:* Maria Louisa Brandi

Ashley Grossman      The clinical use of genetic information in the  
management of pituitary tumors and other endocrine  
tumor syndromes  
Sunita K.      Dideoxy fingerprinting for detection of mutations in  
Agarwal      the MEN1 gene  
Mark Hughes      Single cell diagnostics

**6. New molecular strategies**

*Moderator:* Nancy Cooke

Rob Burgess      Novel knockout strategies for mouse mutagenesis  
Pamela Mellon      Targeted Oncogenesis in Transgenic Mice  
William Chin      Strategies for the identification of new trans-acting  
factors

**7. Longterm complications of GH treatment**

*Moderator:* Richard Robbins

**Panel:**

Charles Sklar

Steve Shalet

Oncological risk in children and adults treated  
with growth hormone

Bengt-Ake Bengtsson

**8. Novel or controversial therapeutic uses of GH**

*Moderator:* Marcello Delano Bronstein

G. Michael Besser

Growth Hormone Replacement in Adults

David N. Herndon

Treatment of burn patients

Vivien Herman-

GH impact on cardiovascular function

Bonert